Panion will not renew Letter of Intent with GeneQuine

The board of directors for Panion Animal Health AB decided at their meeting of 4 December 2017 to
focus Panion's efforts on the development of the epilepsy project. This means that we will no longer pursue the dialogue and cooperation with GeneQuine Biotherapeutics GmbH with regards to their veterinary gene therapy projects. The mutually agreed Letter of Intent will therefore not be sought renewed or extended upon expiry on the 31 December 2017. The decision was taken for business reasons with the aim to focus on the opportunities that best fit with Panion's strategic plans and have the potential to create the best future value for Panion's shareholders.

"Panion will continue to evaluate human medicines projects that may carry great potential for development in veterinary medicine" says Anja Holm, CEO of Panion. 


For further information, please contact:

Anja E. H. Holm, CEO | + 45-22 94 66 00 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 


Panion Animal Health AB has received the European Medicines Agency's acceptance of the classification as MUMS (Minor Use Minor Species) for our epilepsy product for both dogs and cats. The request for classification was submitted to the Committee for Medicinal Products for Veterinary Use (CVMP) in the European Medicines Agency (EMA) earlier in 2017 and has now been successfully evaluated. 


Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene's drug vector CG01. Initial results from CombiGene's long-term study in rats was released yesterday in a message, which is highly relevant for Panion's development of the product for epilepsy in dogs.


Panion has an active status as SME (Small and Medium-sized Enterprise) - at the European Medicines Agency (EMA), which gives access to a number of benefits, information sources, and financial incentives. CEO Anja Holm attended the SME InfoDay on Friday 17 November at the EMA's offices where agency officials together with scientific and regulatory experts from the European Network presented developments and were ready to meet and discuss with companies on an informal basis.


Period July-September 

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -923 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)

Period January-Sept 

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -3 501 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)


Press releases and reports via E-mail.